MX2015001695A - Regimenes de tratamiento. - Google Patents
Regimenes de tratamiento.Info
- Publication number
- MX2015001695A MX2015001695A MX2015001695A MX2015001695A MX2015001695A MX 2015001695 A MX2015001695 A MX 2015001695A MX 2015001695 A MX2015001695 A MX 2015001695A MX 2015001695 A MX2015001695 A MX 2015001695A MX 2015001695 A MX2015001695 A MX 2015001695A
- Authority
- MX
- Mexico
- Prior art keywords
- treatment regimes
- treatment
- hssd
- disorders
- compounds
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/095—Oxytocins; Vasopressins; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Zoology (AREA)
- Gynecology & Obstetrics (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Pregnancy & Childbirth (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261679999P | 2012-08-06 | 2012-08-06 | |
| PCT/US2013/053843 WO2014025814A1 (en) | 2012-08-06 | 2013-08-06 | Treatment regimens |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2015001695A true MX2015001695A (es) | 2015-09-28 |
Family
ID=50068530
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015001695A MX2015001695A (es) | 2012-08-06 | 2013-08-06 | Regimenes de tratamiento. |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US9517254B2 (https=) |
| EP (1) | EP2879680A4 (https=) |
| JP (2) | JP2015524474A (https=) |
| KR (4) | KR20230136142A (https=) |
| CN (2) | CN104884060A (https=) |
| AU (2) | AU2013299725A1 (https=) |
| BR (1) | BR112015002687A2 (https=) |
| CA (1) | CA2881388A1 (https=) |
| EA (1) | EA201590349A1 (https=) |
| HK (2) | HK1211239A1 (https=) |
| IL (1) | IL237150B (https=) |
| MX (1) | MX2015001695A (https=) |
| SG (3) | SG10201709967YA (https=) |
| WO (1) | WO2014025814A1 (https=) |
| ZA (1) | ZA201501562B (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UY36742A (es) * | 2016-06-17 | 2016-12-30 | S1 Biopharma Inc | Métodos para el tratamiento de mujeres con trastorno del deseo sexual hipoactivo (hsdd) con tratamiento de combinación de bupropión y trazodona |
| WO2023168023A1 (en) | 2022-03-04 | 2023-09-07 | Reset Pharmaceuticals, Inc. | Co-crystals or salts comprising psilocin |
| WO2025042884A2 (en) * | 2023-08-21 | 2025-02-27 | Kuleon Llc | Serotonin receptor modulators for the treatment of addictions and overdoses |
| US11977085B1 (en) | 2023-09-05 | 2024-05-07 | Elan Ehrlich | Date rape drug detection device and method of using same |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4687771A (en) * | 1985-11-01 | 1987-08-18 | Bristol-Myers Company | Method for treatment of male impotence |
| DE4321965A1 (de) * | 1993-07-01 | 1995-01-12 | Cytech Biomedical Inc | Oxytocin-haltige Zusammensetzung sowie die Verwendung derselben als Mittel, insbesondere Nasenspray zur Behandlung sexueller Dysfunktionen |
| US6337328B1 (en) | 1999-03-01 | 2002-01-08 | Sepracor, Inc. | Bupropion metabolites and methods of use |
| JP2002322085A (ja) * | 2001-04-26 | 2002-11-08 | Kazuhito Tomizawa | 知的機能障害治療剤 |
| UA78974C2 (en) * | 2001-10-20 | 2007-05-10 | Boehringer Ingelheim Pharma | Use of flibanserin for treating disorders of sexual desire |
| ES2353690T3 (es) | 2002-10-03 | 2011-03-04 | Neuropharmacology Services, Llc | Oxitocina para su uso en el tratamiento del autismo y del trastorno de asperger. |
| WO2004078147A2 (en) * | 2003-03-05 | 2004-09-16 | Pr Pharmaceuticals | Oxytocin controlled release formulations and methods of using same |
| AU2005235422B2 (en) | 2004-04-22 | 2011-08-11 | Boehringer Ingelheim International Gmbh | New pharmaceutical compositions for the treatment of sexual disorders II |
| CN1946404A (zh) * | 2004-04-22 | 2007-04-11 | 贝林格尔·英格海姆国际有限公司 | 用于治疗性功能疾病ⅱ的新颖药物组合物 |
| US20060004076A1 (en) | 2004-06-30 | 2006-01-05 | Inflabloc Pharmaceuticals, Inc. | Co-administration of dehydroepiandrosterone (DHEA) congener with pharmaceutically active agents for treating inflammation |
| EP1827450A4 (en) | 2004-11-17 | 2009-04-22 | Cypress Bioscience Inc | METHOD FOR REDUCING THE SIDE EFFECTS OF TREATMENT WITH MIRTAZAPINE |
| WO2006096435A1 (en) * | 2005-03-04 | 2006-09-14 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions for the treatment and/or prevention of depression |
| US9023793B2 (en) * | 2006-09-29 | 2015-05-05 | Retrophin, Inc. | Intranasal carbetocin formulations and methods for the treatment of autism |
| MX2009004798A (es) * | 2006-10-31 | 2009-08-12 | Janssen Pharmaceutica Nv | Tratamiento de los trastornos generalizados del desarrollo. |
| WO2008075162A2 (en) * | 2006-12-15 | 2008-06-26 | Pfizer Limited | Selective mu opioid receptor antagonists for the treatment of female sexual dysfunction |
| WO2009016488A2 (en) * | 2007-08-02 | 2009-02-05 | Compugen, Ltd. | Compositions comprising tetracyclic antidepressants for treatment of cancer and related methods |
| AU2009282822A1 (en) * | 2008-08-21 | 2010-02-25 | Richter Gedeon Nyrt. | Methods for treating CNS disorders |
| EP2389187B1 (en) * | 2009-01-20 | 2016-11-16 | Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center | Sorbic and benzoic acid and derivatives thereof enhance the activity of a neuropharmaceutical |
| WO2011140608A1 (en) | 2010-05-14 | 2011-11-17 | Keating Charlotte L | Neuropsychopharmacological treatment regimes for treating psychological disorders |
| EP2571360A4 (en) * | 2010-05-19 | 2013-07-31 | Univ North Carolina | METHOD AND FORMULATIONS FOR OXYTOCIN TREATMENT OF DRUG ABUSE AND PSYCHIATRIC AND OTHER DISORDERS |
| WO2012016229A2 (en) * | 2010-07-30 | 2012-02-02 | The Regents Of The University Of California | Oxytocin treatment to improve memory and modify blood glucose |
| SG10201609297VA (en) * | 2011-04-04 | 2016-12-29 | S1 Biopharma Inc | Treatment regimens |
-
2013
- 2013-08-06 HK HK15112183.5A patent/HK1211239A1/xx unknown
- 2013-08-06 HK HK16102368.2A patent/HK1214505A1/zh unknown
- 2013-08-06 BR BR112015002687A patent/BR112015002687A2/pt not_active IP Right Cessation
- 2013-08-06 CA CA2881388A patent/CA2881388A1/en not_active Abandoned
- 2013-08-06 CN CN201380052215.1A patent/CN104884060A/zh active Pending
- 2013-08-06 WO PCT/US2013/053843 patent/WO2014025814A1/en not_active Ceased
- 2013-08-06 US US14/420,112 patent/US9517254B2/en active Active
- 2013-08-06 KR KR1020237027646A patent/KR20230136142A/ko not_active Ceased
- 2013-08-06 EP EP13827390.9A patent/EP2879680A4/en not_active Withdrawn
- 2013-08-06 EA EA201590349A patent/EA201590349A1/ru unknown
- 2013-08-06 AU AU2013299725A patent/AU2013299725A1/en not_active Abandoned
- 2013-08-06 KR KR1020157006024A patent/KR20150063039A/ko not_active Ceased
- 2013-08-06 KR KR1020207031031A patent/KR20200128437A/ko not_active Ceased
- 2013-08-06 SG SG10201709967YA patent/SG10201709967YA/en unknown
- 2013-08-06 SG SG11201500919PA patent/SG11201500919PA/en unknown
- 2013-08-06 CN CN201710010422.0A patent/CN106924259A/zh active Pending
- 2013-08-06 SG SG10201908587P patent/SG10201908587PA/en unknown
- 2013-08-06 MX MX2015001695A patent/MX2015001695A/es unknown
- 2013-08-06 JP JP2015526649A patent/JP2015524474A/ja not_active Ceased
- 2013-08-06 KR KR1020257008033A patent/KR20250041078A/ko active Pending
-
2015
- 2015-02-08 IL IL237150A patent/IL237150B/en active IP Right Grant
- 2015-03-06 ZA ZA2015/01562A patent/ZA201501562B/en unknown
-
2018
- 2018-05-30 JP JP2018103554A patent/JP2018150357A/ja active Pending
- 2018-07-11 AU AU2018205121A patent/AU2018205121A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| KR20200128437A (ko) | 2020-11-12 |
| AU2018205121A1 (en) | 2018-07-26 |
| CN106924259A (zh) | 2017-07-07 |
| AU2013299725A1 (en) | 2015-03-26 |
| HK1211239A1 (en) | 2016-05-20 |
| SG10201908587PA (en) | 2019-10-30 |
| KR20230136142A (ko) | 2023-09-26 |
| CA2881388A1 (en) | 2014-02-13 |
| ZA201501562B (en) | 2017-11-29 |
| EP2879680A4 (en) | 2016-06-01 |
| US9517254B2 (en) | 2016-12-13 |
| KR20250041078A (ko) | 2025-03-25 |
| KR20150063039A (ko) | 2015-06-08 |
| IL237150B (en) | 2018-07-31 |
| US20150150946A1 (en) | 2015-06-04 |
| SG10201709967YA (en) | 2018-01-30 |
| WO2014025814A1 (en) | 2014-02-13 |
| IL237150A0 (en) | 2015-04-30 |
| HK1214505A1 (zh) | 2016-07-29 |
| BR112015002687A2 (pt) | 2019-12-17 |
| EP2879680A1 (en) | 2015-06-10 |
| CN104884060A (zh) | 2015-09-02 |
| SG11201500919PA (en) | 2015-04-29 |
| JP2018150357A (ja) | 2018-09-27 |
| JP2015524474A (ja) | 2015-08-24 |
| EA201590349A1 (ru) | 2015-07-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2015009104A (es) | Composiciones en solución sólida y uso en el tratamiento de enfermedades cardiovasculares. | |
| GT201500051A (es) | Inhibidores de glucosilceramida sintasa | |
| AR091837A1 (es) | Compuestos para inmunoterapia dirigida | |
| MX2014014166A (es) | Metodos para mejorar la seguridad del transporte de la barrera hematoencefalica. | |
| MX2015011434A (es) | Partículas inmunomodificadoras para el tratamiento de la inflamación. | |
| ECSP14017269A (es) | Compuestos para tratar la atrofia muscular espinal | |
| EA201401077A1 (ru) | Биспецифические антитела к человеческому tweak и человеческому il17 и их применения | |
| PT3297644T (pt) | Métodos para tratar distúrbios do espetro do autismo e sintomas associados | |
| PY1337526A (es) | Métodos para tratar o prevenir asma administrando un antagonista de IL-4R. | |
| PH12016500094A1 (en) | Autotaxin inhibitors | |
| NI201400089A (es) | COMPUESTOS DE OXAZOLIDIN - 2 - ONA Y USOS DE LOS MISMOS COMO INHIBIDORES DE LA PI3Ks | |
| EA201500314A1 (ru) | Лекарственные формы энзалутамида | |
| ECSP14024526A (es) | Derivados bicíclicos de pirazinona | |
| CU20140048A7 (es) | Novedosos derivados de purina útiles en el tratamiento del cáncer y trastornos neurodegenerativos | |
| CO6940374A2 (es) | Composiciones, usos y métodos para tratamiento de trastornos y enfermedades metabólicas | |
| GB201209613D0 (en) | New compounds | |
| CL2015000956A1 (es) | Compuestos derivados de pirrolotriazinona como inhibidores de pi3k; composicion farmaceutica que los comprende; combinacion farmaceutica; uso para tratar enfermedades respiratorias, autoinmunes, trastornos neurologicos, cardiovasculares, metabolicos, entre otros. | |
| EA201591616A1 (ru) | Трифторметил-замещенные аннелированные пиримидины и их применение | |
| DOP2014000255A (es) | Uracilos sustituidos bicíclicamente y uso de los mismos | |
| ECSP14017586A (es) | Derivados de tetrahidro-quinazolinona | |
| CR20150248A (es) | Derivados de oxazolidin-2-ona-pirimidina | |
| HUE037179T2 (hu) | Gyógyászati kompozíciók izom-rendellenességek kezelésére | |
| BR112014026326A2 (pt) | composição para tratamento de distúrbios metabólicos | |
| EA201690880A1 (ru) | Тетрациклические ингибиторы аутотаксина | |
| MX376782B (es) | Métodos de administración de composiciones de amantadina. |